Highlighting survival with yttrium-90 radioembolization therapy in unresectable hepatocellular carcinoma

Affiliations

Internal Medicine, Advocate Lutheran General Hospital

Medical Oncology, Advocate Lutheran General Hospital

Abstract

Unresectable hepatocellular carcinoma has several different therapeutic options, including targeted agents as well as locoregional therapy. Yttrium-90 (Y90) radioembolization therapy is an established treatment for unresectable disease and has been compared to other locoregional options as well as different targeted therapies. Newer case series are also reporting a potential benefit to the addition of immunotherapy to Y90 radioembolization. Here we report a case of prolonged survival in a patient whose treatment course included Y90 radioembolization along with sorafenib and nivolumab.

Document Type

Article

PubMed ID

32550079

Teammate Access

Link to Full Text

 

Share

COinS